Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 12Tumor-Agnostic 6Breast 6Thoracic 2Other hematologic neoplasm 2Head & Neck 2Gastrointestinal 2Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1Classical hematology 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease Progression 1

Interventions

Paclitaxel 108Carboplatin 97pembrolizumab 64Cisplatin 63Cyclophosphamide 45Bevacizumab 35Taxes 31Gemcitabine 28liposomal doxorubicin 27Topotecan 26fludarabine 25olaparib 22Nivolumab 20Docetaxel 20Radiotherapy 18Brachytherapy 17veliparib 16Magnetic Resonance Spectroscopy 16Doxorubicin 16Biopsy 15Radiation 14niraparib 13aldesleukin 13Specimen Handling 13Platinum 13Oxaliplatin 13Filgrastim 13Albumin-Bound Paclitaxel 12atezolizumab 11Interleukin-2 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × copanlisib × Gynecologic × Clear all
NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡